The company conducting the first government-approved tests in people of a therapy developed using human embryonic stem cells abruptly announced that it was halting the study. George Q. Daley, HMS professor of biological chemistry and molecular pharmacology at Children’s Hospital Boston, is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?